Cancer immunotherapy has revolutionised cancer treatment, with immune checkpoint
blockade (ICB) therapy and adoptive cell therapy (ACT) increasingly becoming standard of …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

The past decade has witnessed the accelerating development of immunotherapies for
cancer treatment. Immune checkpoint blockade therapies and chimeric antigen receptor …

Immunotherapy has emerged as an effective strategy for the prevention and treatment of a
variety of diseases, including cancer, infectious diseases, inflammatory diseases, and …

Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved
in inhibition of apoptosis and regulation of cell cycle. These functional attributes make …

Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery
more than two decades ago, the use of survivin as a target for cancer therapeutics has …

Although radiotherapy has been used for over a century to locally control tumor growth,
alone it rarely induces an abscopal response or systemic antitumor immunity capable of …

The expression “immunogenic cell death”(ICD) refers to a functionally unique form of cell
death that facilitates (instead of suppressing) a T cell-dependent immune response specific …

Although the discovery and characterization of multiple tumor antigens have sparked the
development of many antigen/derived cancer vaccines, many are poorly immunogenic and …

Peptide-based anticancer vaccination aims at stimulating an immune response against one
or multiple tumor-associated antigens (TAAs) following immunization with purified …